285 related articles for article (PubMed ID: 33208160)
1. Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study.
Lucroy MD; Clauson RM; Suckow MA; El-Tayyeb F; Kalinauskas A
BMC Vet Res; 2020 Nov; 16(1):447. PubMed ID: 33208160
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
[TBL] [Abstract][Full Text] [Related]
4. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
Lana S; U'ren L; Plaza S; Elmslie R; Gustafson D; Morley P; Dow S
J Vet Intern Med; 2007; 21(4):764-9. PubMed ID: 17708397
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
6. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.
Finotello R; Stefanello D; Zini E; Marconato L
Vet Comp Oncol; 2017 Mar; 15(1):25-35. PubMed ID: 25623994
[TBL] [Abstract][Full Text] [Related]
7. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
Batschinski K; Nobre A; Vargas-Mendez E; Tedardi MV; Cirillo J; Cestari G; Ubukata R; Dagli MLZ
Can Vet J; 2018 Sep; 59(9):967-972. PubMed ID: 30197439
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of first-line adjuvant anthracycline vs metronomic-based chemotherapy protocols in the treatment of stage I and II canine splenic haemangiosarcoma.
Treggiari E; Borrego JF; Gramer I; Valenti P; Harper A; Finotello R; Toni C; Laomedonte P; Romanelli G
Vet Comp Oncol; 2020 Mar; 18(1):43-51. PubMed ID: 31648405
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
Sorenmo KU; Baez JL; Clifford CA; Mauldin E; Overley B; Skorupski K; Bachman R; Samluk M; Shofer F
J Vet Intern Med; 2004; 18(2):209-13. PubMed ID: 15058772
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome in 20 cases of lingual hemangiosarcoma in dogs: 1996-2011.
Burton JH; Powers BE; Biller BJ
Vet Comp Oncol; 2014 Sep; 12(3):198-204. PubMed ID: 22905712
[TBL] [Abstract][Full Text] [Related]
14. The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma.
Alexander CK; Cronin KL; Silver M; Gardner HL; London C
J Small Anim Pract; 2019 Jan; 60(1):32-37. PubMed ID: 30209807
[TBL] [Abstract][Full Text] [Related]
15. Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma.
Musser ML; Coto GM; Lingnan Y; Mochel JP; Johannes CM
PLoS One; 2022; 17(12):e0279594. PubMed ID: 36548371
[TBL] [Abstract][Full Text] [Related]
16. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
[TBL] [Abstract][Full Text] [Related]
17. VAC protocol for treatment of dogs with stage III hemangiosarcoma.
Alvarez FJ; Hosoya K; Lara-Garcia A; Kisseberth W; Couto G
J Am Anim Hosp Assoc; 2013; 49(6):370-7. PubMed ID: 24051260
[TBL] [Abstract][Full Text] [Related]
18. Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy.
Faroni E; Sabattini S; Guerra D; Iannuzzi C; Chalfon C; Agnoli C; Stefanello D; Polton G; Ramos S; Aralla M; Ciaccini R; Foglia A; Okonji S; Marconato L
Vet Comp Oncol; 2023 Mar; 21(1):123-130. PubMed ID: 36633399
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011-2014).
Moore AS; Rassnick KM; Frimberger AE
J Am Vet Med Assoc; 2017 Sep; 251(5):559-565. PubMed ID: 28828962
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and adverse events of anthracycline and propranolol combination in five dogs with stage 3 hemangiosarcoma.
Terauchi M; Fujii Y; Goto S; Iwasaki R; Yoshikawa R; Mori T
Open Vet J; 2023 Jun; 13(6):801-806. PubMed ID: 37545711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
